Coherus Oncology, Inc. filings document an oncology operating company with Nasdaq-listed common stock and disclosures tied to LOQTORZI commercialization, antibody immunotherapy development and capital formation. Form 8-K reports cover operating results and business updates, preliminary financial information, clinical supply arrangements involving tagmokitug, and equity transactions under shelf registration, at-the-market and underwritten public offering structures.
Proxy and other filings describe board elections, executive compensation, equity awards, shareholder voting matters, registered securities, governance practices, risk disclosures and the company's capital structure, including common stock issuance and offering-related agreements.
Coherus Oncology, Inc. filed a prospectus supplement tied to its existing Sales Agreement with TD Securities (USA) LLC (TD Cowen), allowing it to sell shares of common stock from time to time in an at-the-market offering program. The company may offer and sell common stock having an aggregate offering price of up to $64,880,054 through or to TD Cowen under this arrangement.
The filing also includes a legal opinion from Latham & Watkins LLP on the validity of the common stock to be issued under the Sales Agreement, along with the related consent and cover page interactive data file as exhibits.
Coherus Oncology, Inc. is registering and offering up to $64,880,054 of its common stock through an at‑the‑market sales program with TD Cowen under an existing Form S-3 shelf. TD Cowen may sell shares into the Nasdaq Global Market under the symbol CHRS and will receive up to 3.0% of gross proceeds as commissions.
The company intends to use any net proceeds for general corporate purposes, including working capital, research and development, commercial activities and capital spending. Coherus reports preliminary unaudited net revenue from continuing operations of approximately $12.7 million for the quarter and $42.2 million for the year ended December 31, 2025, up from $7.7 million and $26.4 million a year earlier, and estimates cash, cash equivalents and marketable securities of about $172.1 million as of December 31, 2025.
Coherus Oncology’s Chief Financial Officer reports a small tax-related share withholding. On January 20, 2026, 1,715 shares of Coherus Oncology, Inc. common stock were automatically withheld by the company at $1.55 per share to cover tax liabilities tied to vesting restricted stock units. This was reported under transaction code F, which typically reflects tax withholding rather than an open‑market trade.
After this withholding, the CFO directly beneficially owned 21,236 shares of Coherus common stock. The footnote clarifies that no shares were sold by the reporting person; the shares were retained by the issuer to satisfy taxes due on equity compensation.
Coherus Oncology President & CEO Dennis M. Lanfear reported an automatic share withholding related to equity compensation. On January 20, 2026, the issuer withheld 11,839 shares of common stock at $1.55 per share to cover taxes due on the vesting of restricted stock units, and no shares were sold by Lanfear in this transaction. After this withholding, he beneficially owned 673,235 shares directly, plus 432,684 shares held by the Lanfear Revocable Trust and 86,965 shares held by Lanfear Capital Advisors, LLC, both entities associated with him.
Coherus Oncology, Inc. filed a current report to share that it is furnishing preliminary, unaudited financial information for the quarter and fiscal year ended December 31, 2025. The company will present preliminary net revenues and levels of cash, cash equivalents and investments at the 43rd Annual J.P. Morgan Healthcare Conference, with this data included in a slide deck furnished as Exhibit 99.1.
Coherus stresses that its financial closing procedures for this period are not yet complete, so final results may differ materially from the preliminary figures, and its independent registered public accounting firm has not reviewed or audited these results. The presentation also contains forward-looking statements, including projected revenue growth of LOQTORZI, which the company notes are subject to significant risks such as financing needs, market acceptance of its products and litigation risks.
Coherus Oncology, Inc. filed a shelf registration statement on Form S-3 to offer and sell up to $150.0 million of mixed securities, including common stock, preferred stock, debt securities, warrants, and units, from time to time in one or more offerings. Each sale will be detailed in a prospectus supplement describing specific terms and pricing.
The filing replaces a prior registration and, under Rule 415, permits offerings via underwriters, dealers, agents, or direct sales. The company’s common stock trades on Nasdaq as CHRS; the last reported sale price was $1.36 per share on November 12, 2025. Use of proceeds will be described in the applicable prospectus supplement.
Coherus Oncology filed a Form S-8 registering 1,500,000 additional shares of common stock for its 2014 Employee Stock Purchase Plan, as approved by stockholders on June 11, 2025.
The filing adds capacity for employee share purchases under the ESPP. It includes customary exhibits, including a legal opinion from Latham & Watkins LLP, and notes Coherus is an accelerated filer and a smaller reporting company.
Coherus Oncology (CHRS) recast prior financials to reflect discontinued operations after divesting its UDENYCA franchise. The company completed the UDENYCA sale to Intas on April 11, 2025 for upfront, all‑cash consideration of $483.4 million, which included $118.4 million for product inventory. Coherus is also eligible for two additional earn‑out payments of $37.5 million each.
Exhibit 99.1 updates selected sections of the 2024 Form 10‑K to present the biosimilar businesses (UDENYCA, YUSIMRY, CIMERLI) as discontinued operations for the fiscal years ended December 31, 2024 and 2023. The recast information is intended for incorporation by reference into a Form S‑3 expected to be filed on November 13, 2025. The filing limits changes to those necessary for the discontinued operations presentation, maintaining the nature and character of the original disclosures.
Coherus Oncology (CHRS) reported Q3 2025 results. Continuing operations net revenue was $11,571, driven by LOQTORZI revenue of $11,169. Loss from continuing operations was $(44,517). Discontinued operations contributed net income of $8,986, resulting in a quarterly net loss of $(35,531).
The company closed the divestiture of the UDENYCA franchise on April 11, 2025 for upfront cash of $483.4 million, recognizing a net gain of $338.7 million. Proceeds were used to redeem substantially all 2026 convertible notes and to buy out UDENYCA royalty rights for $47.7 million.
As of September 30, 2025, cash and cash equivalents were $103,352 and investments in marketable securities were $88,311. Total assets were $516,519, total liabilities $428,745, and stockholders’ equity was $87,774. Shares outstanding were 116,236,018 at quarter end.
Coherus Oncology (CHRS) reported Q3 2025 results. Continuing operations net revenue was $11,571, driven by LOQTORZI revenue of $11,169. Loss from continuing operations was $(44,517). Discontinued operations contributed net income of $8,986, resulting in a quarterly net loss of $(35,531).
The company closed the divestiture of the UDENYCA franchise on April 11, 2025 for upfront cash of $483.4 million, recognizing a net gain of $338.7 million. Proceeds were used to redeem substantially all 2026 convertible notes and to buy out UDENYCA royalty rights for $47.7 million.
As of September 30, 2025, cash and cash equivalents were $103,352 and investments in marketable securities were $88,311. Total assets were $516,519, total liabilities $428,745, and stockholders’ equity was $87,774. Shares outstanding were 116,236,018 at quarter end.
Coherus Oncology, Inc. (CHRS) reported that it furnished, not filed, a press release announcing financial results for the fiscal quarter ended September 30, 2025. The company disclosed this under Item 2.02 and attached the full text as Exhibit 99.1.
The submission clarifies that the information provided under Item 2.02 and Exhibit 99.1 is not subject to Section 18 liabilities of the Exchange Act and is not incorporated by reference unless specifically stated. The filing also includes the Cover Page Inline XBRL as Exhibit 104.
Coherus Oncology, Inc. (CHRS) reported that it furnished, not filed, a press release announcing financial results for the fiscal quarter ended September 30, 2025. The company disclosed this under Item 2.02 and attached the full text as Exhibit 99.1.
The submission clarifies that the information provided under Item 2.02 and Exhibit 99.1 is not subject to Section 18 liabilities of the Exchange Act and is not incorporated by reference unless specifically stated. The filing also includes the Cover Page Inline XBRL as Exhibit 104.